GSK has been the subject of a number of other research reports. Morgan Stanley reaffirmed an underweight rating on shares of GlaxoSmithKline in a report on Monday, June 17th. Zacks Investment Research downgraded GlaxoSmithKline from a buy rating to a hold rating in a research report on Thursday, April 25th. Finally, Cowen reiterated a hold rating and set a $45.00 price target on shares of GlaxoSmithKline in a research report on Monday, June 10th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have given a buy rating to the stock. GlaxoSmithKline has an average rating of Hold and a consensus target price of $42.66.
GSK stock opened at $40.65 on Tuesday. The company has a quick ratio of 0.48, a current ratio of 0.71 and a debt-to-equity ratio of 7.86. The stock has a market cap of $100.39 billion, a price-to-earnings ratio of 12.86, a PEG ratio of 1.97 and a beta of 0.71. GlaxoSmithKline has a twelve month low of $36.41 and a twelve month high of $42.47. The firm’s 50-day moving average is $40.90.
In other news, Director Plc Glaxosmithkline bought 333,333 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was bought at an average price of $15.00 per share, for a total transaction of $4,999,995.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 10.00% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. Comerica Securities Inc. lifted its position in GlaxoSmithKline by 2.6% during the fourth quarter. Comerica Securities Inc. now owns 12,984 shares of the pharmaceutical company’s stock worth $502,000 after purchasing an additional 326 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of GlaxoSmithKline by 5.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,769,859 shares of the pharmaceutical company’s stock worth $67,626,000 after acquiring an additional 88,148 shares during the last quarter. Norges Bank bought a new position in shares of GlaxoSmithKline in the fourth quarter worth about $17,275,000. Geode Capital Management LLC lifted its holdings in shares of GlaxoSmithKline by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 424,397 shares of the pharmaceutical company’s stock worth $16,216,000 after acquiring an additional 48,476 shares during the last quarter. Finally, Ropes Wealth Advisors LLC lifted its holdings in shares of GlaxoSmithKline by 21.8% in the first quarter. Ropes Wealth Advisors LLC now owns 3,348 shares of the pharmaceutical company’s stock worth $140,000 after acquiring an additional 600 shares during the last quarter. Institutional investors own 11.26% of the company’s stock.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Article: What can cause a stock to outperform?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.